{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:43:02Z","timestamp":1791571382292,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014476","name":"Pfizer BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.biopha.2022.113393","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T13:21:13Z","timestamp":1657545673000},"page":"113393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer"],"prefix":"10.1016","volume":"153","author":[{"given":"Niels A.D.","family":"Guchelaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.G.","family":"van Eerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie L.","family":"Groenland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leni van","family":"Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid M.E.","family":"Desar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry A.L.M.","family":"Eskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L.W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2022.113393_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.biopha.2022.113393_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2022.113393_bib3","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"9940","key":"10.1016\/j.biopha.2022.113393_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.biopha.2022.113393_bib5","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for advanced and refractory desmoid tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2022.113393_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin. Pharmcokinet."},{"issue":"4","key":"10.1016\/j.biopha.2022.113393_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2022.113393_bib8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00228-019-02704-2","article-title":"Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine","volume":"75","author":"Groenland","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113393_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase i trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.biopha.2022.113393_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1620\/tjem.237.173","article-title":"Monitoring serum levels of sorafenib and Its N-oxide is essential for long-term sorafenib treatment of patients with hepatocellular carcinoma","volume":"237","author":"Shimada","year":"2015","journal-title":"Tohoku J. Exp. Med."},{"issue":"3","key":"10.1016\/j.biopha.2022.113393_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/bjc.2012.287","article-title":"Sorafenib in advanced melanoma: a critical role for pharmacokinetics?","volume":"107","author":"P\u00e9cuchet","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2022.113393_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-020-04105-0","article-title":"Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study","volume":"86","author":"Noda","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2022.113393_bib13","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1634\/theoncologist.2011-0439","article-title":"Variability of sorafenib toxicity and exposure over time: a pharmacokinetic\/pharmacodynamic analysis","volume":"17","author":"Boudou-Rouquette","year":"2012","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.biopha.2022.113393_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40262-013-0108-z","article-title":"Exposure\u2013toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma","volume":"53","author":"Fukudo","year":"2014","journal-title":"Clin. Pharmcokinet."},{"issue":"7","key":"10.1016\/j.biopha.2022.113393_bib15","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-11-2484","article-title":"Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia","volume":"18","author":"Peer","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.biopha.2022.113393_bib16","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2217\/pgs-2016-0063","article-title":"Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity","volume":"17","author":"Bins","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.biopha.2022.113393_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/cts.12458","article-title":"Influence of OATP1B1 function on the disposition of sorafenib-\u03b2-D-glucuronide","volume":"10","author":"Bins","year":"2017","journal-title":"Clin. Transl. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2022.113393_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090788","article-title":"Influence of probenecid on the pharmacokinetics and pharmacodynamics of sorafenib","volume":"12","author":"Hussaarts","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2022.113393_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.06.010","article-title":"Therapeutic drug monitoring based precision dosing of oral targeted therapies in oncology: a prospective multicentre study","author":"Groenland","year":"2022","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113393_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000654","article-title":"Therapeutic drug monitoring of oral anticancer drugs: the Dutch Pharmacology Oncology Group\u2013therapeutic drug monitoring protocol for a prospective study","volume":"41","author":"Groenland","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.biopha.2022.113393_bib21","unstructured":"Services UDoHaH. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2013."},{"issue":"2","key":"10.1016\/j.biopha.2022.113393_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ph14020119","article-title":"Feasibility of extrapolating randomly taken plasma samples to trough levels for therapeutic drug monitoring purposes of small molecule kinase inhibitors","volume":"14","author":"van Eerden","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.biopha.2022.113393_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/FTD.0000000000000349","article-title":"Quantification of 11 Therapeutic kinase inhibitors in human plasma for therapeutic drug monitoring using liquid chromatography coupled with tandem mass spectrometry","volume":"38","author":"Herbrink","year":"2016","journal-title":"Ther. Drug Monit."},{"issue":"19","key":"10.1016\/j.biopha.2022.113393_bib24","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113393_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113393_bib26","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research. Sorafenib Clinical Pharmacology and Biopharmaceutics Review 2005.\u00a0\u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2005\/021923_s000_Nexavar_BioPharmR.pdf\u3009."},{"issue":"24","key":"10.1016\/j.biopha.2022.113393_bib27","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1158\/1078-0432.CCR-20-4555","article-title":"Precision dosing of targeted therapies is ready for prime time","volume":"27","author":"Groenland","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2022.113393_bib28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bcp.14185","article-title":"Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose","volume":"86","author":"Westerdijk","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113393_bib29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.biopha.2022.113393_bib30","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-04-2658","article-title":"Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors","volume":"11","author":"Clark","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2022.113393_bib31","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/annonc\/mdi310","article-title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on\/7 days off in patients with advanced, refractory solid tumors","volume":"16","author":"Moore","year":"2005","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113393_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.therap.2021.12.002","article-title":"Pharmacokinetics and therapeutic drug monitoring of anticancer protein\/kinase inhibitors","volume":"77","author":"Bouchet","year":"2022","journal-title":"Therapies"},{"issue":"1","key":"10.1016\/j.biopha.2022.113393_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12032-014-0335-7","article-title":"Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study","volume":"32","author":"Fucile","year":"2014","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113393_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/FTD.0000000000000723","article-title":"Therapeutic drug monitoring of sorafenib in hepatocellular carcinoma patients","volume":"42","author":"Thomas","year":"2020","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.biopha.2022.113393_bib35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2125.2011.03963.x","article-title":"Population pharmacokinetic analysis of sorafenib in patients with solid tumours","volume":"72","author":"Jain","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7\u20138","key":"10.1016\/j.biopha.2022.113393_bib36","first-page":"420","article-title":"Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells","volume":"35","author":"Kuckertz","year":"2012","journal-title":"Onkologie"},{"issue":"7","key":"10.1016\/j.biopha.2022.113393_bib37","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1002\/ijc.32964","article-title":"Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: analysis in real-life settings","volume":"147","author":"Tak","year":"2020","journal-title":"Int. J. Cancer"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222200782X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222200782X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:27:57Z","timestamp":1779967677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222200782X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":37,"alternative-id":["S075333222200782X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113393","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113393"}}